- Cholinergic Agonists
- Accession Number
Drugs that bind to and activate cholinergic receptors.
Drug Drug Description Nicotine A stimulatory alkaloid found in tobacco products that is often used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation. Cevimeline A muscarinic agonist with parasympathomimetic activities that is used for the symptomatic treatment of dry mouth in patients with Sjögren's Syndrome. Carbamoylcholine A direct acting miotic agent administered ophthalmically to decrease intraocular pressure after cataract surgery, and to induce miosis during surgery. Bethanechol A muscarinic agonist used to treat postoperative and postpartum nonobstructive functional urinary retention and neurogenic atony of the bladder with retention. Pilocarpine A muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiotherapy. Varenicline A partial agonist at nicotinic acetylcholine receptors used as an aid in smoking cessation. Acetylcholine A parasympathomimetic neurotransmitter used to induce miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required. Arecoline An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the... Lobeline Investigated for use/treatment in addictions. GTS-21 Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders. Methacholine A parasympathomimetic bronchoconstrictor used to diagnose bronchial hyperreactivity in subjects who do not have clinically apparent asthma. Epibatidine Not Available Xanomeline Xanomeline is under investigation in clinical trial NCT02831231 (Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium). NGX267 Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
- Drugs & Drug Targets